Published in Ann Intensive Care on September 23, 2011
Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit. Br J Clin Pharmacol (2013) 1.28
Erythropoietin; bright future and new hopes for an old drug. J Nephropathol (2012) 1.22
A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice. Br J Pharmacol (2014) 0.86
Investigational agents for treatment of traumatic brain injury. Expert Opin Investig Drugs (2015) 0.84
Erythropoietin reduces acute lung injury and multiple organ failure/dysfunction associated to a scald-burn inflammatory injury in the rat. Inflammation (2015) 0.80
Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care. Crit Care (2012) 0.80
Erythropoietin in the critically ill: do we ask the right questions? Crit Care (2012) 0.78
Blood Transfusions in Dogs and Cats Receiving Hemodialysis: 230 Cases (June 1997-September 2012). J Vet Intern Med (2017) 0.75
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet (2005) 13.77
Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med (2008) 5.89
Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med (2007) 5.63
Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke (2009) 5.28
Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A (2000) 5.20
Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA (2002) 4.09
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09
Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med (2002) 3.87
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A (2001) 3.80
In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A (1998) 3.53
Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A (2004) 3.40
Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol (2005) 3.38
Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int (2010) 3.37
Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood (2005) 3.10
Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood (2003) 2.93
Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol (2004) 2.64
Systemic inflammation after trauma. Injury (2007) 2.62
Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol (2009) 2.57
A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J (2010) 2.52
Erythropoietin during porcine aortic balloon occlusion-induced ischemia/reperfusion injury. Crit Care Med (2008) 2.50
Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation (2002) 2.37
Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med (2003) 2.37
Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med (2000) 2.33
A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 2.32
Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood (1999) 2.30
Deaths: injuries, 2002. Natl Vital Stat Rep (2006) 2.30
Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A (1990) 2.28
Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A (2003) 2.28
Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience (1997) 2.25
Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int (2007) 2.22
Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A (2008) 2.21
Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest (1992) 2.14
Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res (2006) 2.02
Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int (1999) 2.00
Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (2001) 1.94
Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant (2003) 1.94
Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med (1999) 1.92
Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res (2006) 1.89
Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab (2006) 1.68
Therapeutic effects of erythropoietin in murine models of endotoxin shock. Crit Care Med (2009) 1.68
Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res (2006) 1.62
Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int (2006) 1.59
Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc Drugs Ther (2008) 1.57
Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant (2004) 1.56
Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene (2005) 1.56
Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev (2009) 1.53
Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model. Nephrol Dial Transplant (2010) 1.52
Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci U S A (2000) 1.47
Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood (2004) 1.43
Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol (2001) 1.41
Signal transduction in the erythropoietin receptor system. Exp Cell Res (1999) 1.40
Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways. FASEB J (2005) 1.40
Poly(ADP-ribose) polymerase-1 mediated caspase-independent cell death after ischemia/reperfusion. Free Radic Biol Med (2005) 1.39
Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J (2003) 1.36
Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol (2005) 1.34
Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int (2003) 1.33
Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int (2004) 1.26
Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. J Trauma (2008) 1.26
Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2. FASEB J (2004) 1.25
Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem (2004) 1.20
Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant (2001) 1.17
Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol (2004) 1.15
Erythropoiesis in multiply injured patients. J Trauma (2006) 1.13
Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock (2004) 1.12
How to use biomarkers efficiently in acute kidney injury. Kidney Int (2011) 1.08
β Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. J Cell Physiol (2011) 1.07
Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J Clin Invest (2010) 1.06
The polymorphonuclear leukocyte--a new target for erythropoietin. Nephron (2001) 1.05
Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J (2002) 1.05
Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv (2010) 1.04
Erythropoietin decreases cytotoxicity and nitric oxide formation induced by inflammatory stimuli in rat oligodendrocytes. Physiol Res (2005) 1.02
Erythropoietin prevents blood brain barrier damage induced by focal cerebral ischemia in mice. Neurochem Res (2007) 1.02
Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail (2008) 0.98
Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys (2007) 0.98
The impact of ischaemia-reperfusion on the blood vessel. Eur J Anaesthesiol (2009) 0.96
Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. Arthritis Rheum (2005) 0.95
Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg (2005) 0.94
A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock. Mol Med (2011) 0.94
Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci (2005) 0.93
Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischemia-reperfusion injury. Acta Anaesthesiol Scand (2011) 0.92
Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward? J Investig Med (2011) 0.92
Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. Eur J Cardiothorac Surg (2006) 0.92
Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol (2005) 0.90
Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med (2006) 0.89
Erythropoietin-induced optimization of renal function after warm ischemia. J Endourol (2009) 0.84
Erythropoietin in the cerebrospinal fluid of patients with aneurysmal subarachnoid haemorrhage originates from the brain. Brain Res (2003) 0.84
Anemia and blood transfusion in trauma patients admitted to the intensive care unit. J Trauma (2003) 0.84
Signal transduction in the erythropoietin receptor system. Stem Cells (1993) 0.82
The role of erythropoietin therapy in the critically ill. Transfus Med Rev (2006) 0.81
Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome. Heart (2010) 0.78
Effects of combined erythropoietin and epidermal growth factor on renal ischaemia/reperfusion injury: a randomized experimental controlled study. BJU Int (2011) 0.77
Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol (2009) 3.95
Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol (2004) 2.64
Abandon the mouse research ship? Not just yet! Shock (2014) 2.60
C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med (2009) 2.29
Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A (2008) 2.21
Ischemic conditioning protects the uremic heart in a rodent model of myocardial infarction. Circulation (2012) 2.12
Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci U S A (2007) 2.10
GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med (2005) 2.05
On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br J Pharmacol (2003) 1.77
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J (2002) 1.73
Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: role of glycogen synthase kinase-3beta inhibition. Crit Care Med (2006) 1.66
Presentation, diagnosis, and treatment outcome of tuberculous-mediated tubulointerstitial nephritis. Kidney Int (2010) 1.64
Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock (2009) 1.60
Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients. Am J Kidney Dis (2004) 1.60
Peptidoglycan of Staphylococcus aureus causes inflammation and organ injury in the rat. Crit Care Med (2004) 1.57
Role of inducible nitric oxide synthase in the reduced responsiveness of the myocardium to catecholamines in a hyperdynamic, murine model of septic shock. Crit Care Med (2006) 1.54
Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase. J Am Soc Nephrol (2007) 1.53
Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury. Int J Cardiol (2011) 1.52
Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice. Intensive Care Med (2003) 1.52
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol (2004) 1.50
Generation of endogenous hydrogen sulfide by cystathionine gamma-lyase limits renal ischemia/reperfusion injury and dysfunction. Lab Invest (2008) 1.49
Effects of calpain inhibitor I on multiple organ failure induced by zymosan in the rat. Crit Care Med (2002) 1.49
Refinement of animal models of sepsis and septic shock. Shock (2015) 1.48
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med (2004) 1.48
Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br J Pharmacol (2002) 1.47
Inhibition of endogenous hydrogen sulfide formation reduces the organ injury caused by endotoxemia. Br J Pharmacol (2005) 1.45
Predictors of survival and technique success after reinsertion of peritoneal dialysis catheter following severe peritonitis. Perit Dial Int (2006) 1.43
Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res (2005) 1.41
Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther (2004) 1.39
Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. Kidney Int (2013) 1.37
The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation. Mol Pharmacol (2002) 1.29
Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int (2004) 1.26
Caspase and calpain function in cell death: bridging the gap between apoptosis and necrosis. Ann Clin Biochem (2005) 1.26
High glucose-induced oxidative stress causes apoptosis in proximal tubular epithelial cells and is mediated by multiple caspases. FASEB J (2003) 1.24
Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock (2007) 1.23
Noncleavable poly(ADP-ribose) polymerase-1 regulates the inflammation response in mice. J Clin Invest (2004) 1.17
Dexamethasone ameliorates renal ischemia-reperfusion injury. J Am Soc Nephrol (2009) 1.17
Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med (2006) 1.16
GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int (2003) 1.16
PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int (2009) 1.15
Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury. Kidney Int (2002) 1.15
COX-2 in inflammation and resolution. Mol Interv (2006) 1.15
Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med (2006) 1.14
Novel biphasic role for lymphocytes revealed during resolving inflammation. Blood (2008) 1.14
Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock (2004) 1.12
High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock (2004) 1.12
The NLRP3 Inflammasome as a novel player of the intercellular crosstalk in metabolic disorders. Mediators Inflamm (2013) 1.11
Mechanisms of high glucose-induced apoptosis and its relationship to diabetic complications. J Nutr Biochem (2005) 1.11
Diadenosine tetraphosphate protects against injuries induced by ischemia and 6-hydroxydopamine in rat brain. J Neurosci (2003) 1.11
Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock. Am J Respir Crit Care Med (2010) 1.10
Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism. Shock (2003) 1.09
Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. Am J Respir Crit Care Med (2007) 1.09
The peroxisome proliferator-activated receptor-gamma ligand 15-deoxyDelta12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock. Shock (2004) 1.09
Renal postconditioning...pause for thought? Correspondence regarding "Protection against renal ischemia-reperfusion injury by ischemic postconditioning". Transplantation (2013) 1.09
Glycogen synthase kinase-3beta inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock (2006) 1.08
Role of induced nitric oxide in the initiation of the inflammatory response after postischemic injury. Shock (2002) 1.08
Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol (2003) 1.07
Induction of cytokine production in human T cells and monocytes by highly purified lipoteichoic acid: involvement of Toll-like receptors and CD14. Med Sci Monit (2002) 1.06
Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br J Pharmacol (2006) 1.06
Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol (2003) 1.05
Glycogen synthase kinase-3beta inhibition attenuates asthma in mice. Am J Respir Crit Care Med (2007) 1.05
Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta. Diabetes (2008) 1.04
Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum (2003) 1.04
Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin Immunol (2006) 1.04
Nonresolving inflammation in gp91phox-/- mice, a model of human chronic granulomatous disease, has lower adenosine and cyclic adenosine 5'-monophosphate. J Immunol (2009) 1.03
Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther (2006) 1.03
Junctional adhesion molecule-C mediates leukocyte infiltration in response to ischemia reperfusion injury. Arterioscler Thromb Vasc Biol (2009) 1.03
Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int (2006) 1.02
Inhibitors of NADPH oxidase reduce the organ injury in hemorrhagic shock. Shock (2005) 1.02
Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol (2010) 1.01
Glycogen synthase kinase-3beta inhibition attenuates the development of ischaemia/reperfusion injury of the gut. Intensive Care Med (2007) 1.00
Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome. Transplantation (2012) 0.99
Characterisation of cystathionine gamma-lyase/hydrogen sulphide pathway in ischaemia/reperfusion injury of the mouse kidney: an in vivo study. Eur J Pharmacol (2009) 0.98
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein. Intensive Care Med (2004) 0.98
Erythropoietin reduces the development of experimental inflammatory bowel disease. J Pharmacol Exp Ther (2004) 0.98
Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin. Crit Care Med (2004) 0.98
Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Am J Kidney Dis (2009) 0.98
Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury. J Pharmacol Exp Ther (2010) 0.97
Substance P increases neutrophil adhesion to human umbilical vein endothelial cells. Br J Pharmacol (2003) 0.97
Pharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock. Dis Model Mech (2012) 0.97
Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. Eur J Pharmacol (2002) 0.96
Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med Sci Monit (2002) 0.96
Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock (2008) 0.96
TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons. Proc Natl Acad Sci U S A (2013) 0.95
SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats. Free Radic Biol Med (2009) 0.95